Free Trial Information
BioCentury | Sep 21, 2018
Emerging Company Profile

Aprinoia tackles tau

...to target the different tau species. The company hopes to begin clinical testing of its tau therapeutics...
Read More
BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
Read More
BioCentury | Oct 20, 2014
Clinical News

Mibefradil dihydrochloride: Phase Ib started

...and angina from the market due to the potential for multiple drug-drug interactions. In August, Tau Therapeutics LLC...
Read More
BioCentury | Sep 29, 2014
Company News

Tau Therapeutics, Xdynia deal

...Phase II trial of a T-type calcium channel inhibitor to treat neuropathic pain in 2015. Tau Therapeutics LLC...
Read More
BioCentury | May 19, 2014
Company News

AC Immune, Piramal Enterprises deal

AC Immune granted Piramal's Piramal Imaging division exclusive, worldwide rights to develop and commercialize microtubule-associated protein tau (MAPT; tau; FTDP-17 ) PET tracers to diagnose and manage Alzheimer's disease and potential tau-related disorders. AC Immune will...
Read More
BioCentury | May 5, 2014
Clinical News

Tau Therapeutics preclinical data

...see BioCentury, April 28). Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets Temodar temozolomide. Tau Therapeutics LLC...
Read More
BioCentury | Jan 28, 2013
Company News

Tau Therapeutics management update

Tau Therapeutics LLC , Charlottesville, Va. Business: Cancer Hired: Bruce Silver as CMO WIR Staff cancer...
Read More
BioCentury | Jan 14, 2013
Clinical News

Mibefradil: Phase I data

...for multiple drug-drug interactions. Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets Temodar temozolomide. Tau Therapeutics LLC...
Read More
BioCentury | Dec 24, 2012
Financial News

Tau Therapeutics completes venture financing

Tau Therapeutics LLC , Charlottesville, Va. Business: Cancer Date completed: 12/18/12 Type: Venture financing Raised: $3 million Investors: Individual investors WIR Staff...
Read More
BioCentury | Jun 11, 2012
Emerging Company Profile

Xdynia: T type relief

...Xdynia LLC spun out from Tau Therapeutics Inc . this year to develop oral small molecule inhibitors...
...to raise $5-$10 million in a series A round by 2H13. Companies and Institutions Mentioned Tau Therapeutics...
...Maricich, Andrew Krouse, Tim Macdonald and Lloyd Gray University collaborators: University of Virginia Corporate partners: Tau Therapeutics...
Read More
Items per page:
1 - 10 of 15
BioCentury | Sep 21, 2018
Emerging Company Profile

Aprinoia tackles tau

...to target the different tau species. The company hopes to begin clinical testing of its tau therapeutics...
Read More
BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
Read More
BioCentury | Oct 20, 2014
Clinical News

Mibefradil dihydrochloride: Phase Ib started

...and angina from the market due to the potential for multiple drug-drug interactions. In August, Tau Therapeutics LLC...
Read More
BioCentury | Sep 29, 2014
Company News

Tau Therapeutics, Xdynia deal

...Phase II trial of a T-type calcium channel inhibitor to treat neuropathic pain in 2015. Tau Therapeutics LLC...
Read More
BioCentury | May 19, 2014
Company News

AC Immune, Piramal Enterprises deal

AC Immune granted Piramal's Piramal Imaging division exclusive, worldwide rights to develop and commercialize microtubule-associated protein tau (MAPT; tau; FTDP-17 ) PET tracers to diagnose and manage Alzheimer's disease and potential tau-related disorders. AC Immune will...
Read More
BioCentury | May 5, 2014
Clinical News

Tau Therapeutics preclinical data

...see BioCentury, April 28). Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets Temodar temozolomide. Tau Therapeutics LLC...
Read More
BioCentury | Jan 28, 2013
Company News

Tau Therapeutics management update

Tau Therapeutics LLC , Charlottesville, Va. Business: Cancer Hired: Bruce Silver as CMO WIR Staff cancer...
Read More
BioCentury | Jan 14, 2013
Clinical News

Mibefradil: Phase I data

...for multiple drug-drug interactions. Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets Temodar temozolomide. Tau Therapeutics LLC...
Read More
BioCentury | Dec 24, 2012
Financial News

Tau Therapeutics completes venture financing

Tau Therapeutics LLC , Charlottesville, Va. Business: Cancer Date completed: 12/18/12 Type: Venture financing Raised: $3 million Investors: Individual investors WIR Staff...
Read More
BioCentury | Jun 11, 2012
Emerging Company Profile

Xdynia: T type relief

...Xdynia LLC spun out from Tau Therapeutics Inc . this year to develop oral small molecule inhibitors...
...to raise $5-$10 million in a series A round by 2H13. Companies and Institutions Mentioned Tau Therapeutics...
...Maricich, Andrew Krouse, Tim Macdonald and Lloyd Gray University collaborators: University of Virginia Corporate partners: Tau Therapeutics...
Read More
Items per page:
1 - 10 of 15